[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervix-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervix-pregnancy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100394876","effects-of-systematic-cervical-exam-training-on-labor-and-delivery-care-100394876",false,"NCT04421768","Effects of Systematic Cervical Exam Training on Labor and Delivery Care","Inclusion Criteria:\n\nHealthcare providers:\n\n• physicians, midwives, and labor and delivery nurses working on the Labor and Delivery unit within the Wake Forest Baptist Birth Center\n\nPatients:\n\n• any pregnant women receiving care on the Labor and Delivery unit of Wake Forest Baptist Birth Center\n\nExclusion Criteria:\n\nHealthcare providers:\n\n• none\n\nPatients:\n\n* placenta previa\n* vasa previa\n* any other contraindication to cervical exam",true,"ALL",{"count":18,"type":19},1125,"ESTIMATED","INTERVENTIONAL",[22],"NA","All physicians, nurses, and nurse midwives working on Labor and Delivery will be required to complete cervical exam simulation training. Data before and after institution of the training will be compared to determine if the training leads to less cervical exams during labor and increases consistency between examiners",[25,26,27],"Delivery Problem","Cervix; Pregnancy","Pregnancy Related",[29,30,31],"vaginal delivery","labor cervical exam","labor and delivery","RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":36},"2020-07-23",{"date":40,"type":19},"2026-12",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100458204","prospective-evaluation-of-pathways-for-preterm-birth-100458204","NCT05246579","Prospective Evaluation of Pathways for Preterm Birth","Prospective Evaluation of Pathways for Preterm Birth: The PEPP Study","PEPP","Inclusion Criteria:\n\n* Maternal age from 18 to 45 years of age.\n* Singleton gestation.\n\nExclusion Criteria:\n\n* Treatment with vaginal progesterone or intramuscular progestogen within the previous 4 weeks.\n* History of congestive heart failure, chronic renal failure, or uncontrolled diabetes mellitus, or diabetes mellitus with evidence of end organ dysfunction secondary to vascular disease.\n* Current pregnancy with a major fetal anomaly or known chromosomal abnormality.\n* The subject has a marked uterine anatomic malformation that may alter pregnancy duration such as a septated uterus, unicornuate uterus, or uterine didelphys.\n* The subject is considered not capable or unwilling to undergo study procedures and requirements.\n* The subject is symptomatic with vaginal bleeding at enrollment visit.","FEMALE","18 Years","45 Years",{"count":57,"type":19},240,"OBSERVATIONAL","This is a single center, prospective cohort study of pregnant patients at high risk for spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's with a short cervix and patient's symptomatic for preterm birth will be included. A control cohort of nulliparous patients without a short cervix will be recruited to provide baseline data. Plan to enroll 240 patients identified through our ultrasound unit with goal of 60 patients in each group.",[61,26],"Preterm Birth",[63,61,64],"Cervical Length","Inflammation","2025-06-27",{"date":67,"type":36},"2025-07-02",{"date":69,"type":36},"2022-02-04",{"date":71,"type":19},"2026-06-01",{"name":73,"class":43},"John O'Brien, MD",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":82,"targetDuration":84,"studyType":58,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100542187","pregnancy-repository-100542187","NCT06339606","Pregnancy Repository","Repository for Biospecimens From Pregnant Patients","PR","Inclusion Criteria:\n\n* Consenting pregnant adults (age 18-45 years) with known or suspected risk for abnormal placentation (Abnormal Placentation Group)\n* Consenting pregnant adults (age 18-45 years) with low-risk pregnancies (Control Group)\n* Singleton or multiple pregnancy\n* Ongoing clinical care at the participating sites, with delivery at the same institution.\n\nExclusion Criteria:\n\n* None",{"count":83,"type":19},7000,"9 Months","An essential part of clinical research is the availability and accessibility of human biospecimens for the identification of biomarkers, new treatments and measurement of response to therapy. Proteins, RNA and DNA can be extracted and studied as well. This is a critical first step in performing many fundamental molecular biology experiments. A variety of biospecimens are utilized for research including but not limited to normal and malignant tissues, blood, and other body fluids.\n\nIn order to obtain high-quality biospecimens, they must be acquired serially, stored according to current standards, and matched with clinical information for maximum value. As such, the investigators would like to create a repository of biospecimens collected from pregnant patients who are seen at Mount Sinai Hospital and other research hospitals in Toronto. Mount Sinai provides personnel and infrastructure to serve the largest (7500 births\u002Fyear) and highest complex Maternity program in Ontario. Of the 7500 patients a year, at least 2500 are considered high risk pregnancies, where there's a possibility of preeclampsia, placenta accreta and a host of other complications. For this study, biological specimens - blood, cervical and placental samples - will be collected from these high-risk groups in order to better understand the causes of the underlying conditions.",[27,87,88,89,26],"Fetal Growth Retardation","Placental Insufficiency","Preeclampsia","NOT_YET_RECRUITING","2024-04-22",{"date":93,"type":36},"2024-04-24",{"date":95,"type":19},"2024-05-01",{"date":97,"type":19},"2031-04-30",{"name":99,"class":43},"Sunnybrook Health Sciences Centre",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":107,"targetDuration":84,"studyType":58,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100540925","optimization-of-cervical-collections-in-pregnancy-100540925","NCT06323187","Optimization of Cervical Collections in Pregnancy","OCCP","Inclusion Criteria:\n\n* Confirmed pregnancy Before 30w0d gestation for pregnant participants\n* Regular menses within previous month for non-pregnant participants\n* 18-45 years old\n\nExclusion Criteria:\n\n* Bleeding \\>5 days in first trimester for pregnant participants\n* Ruptured membranes for pregnant participants\n* Currently menstruating for non-pregnant participants",{"count":108,"type":19},2600,"Fetal cells are not easily obtained from pregnant patients; this curtails testing to assess the health of the fetus and the mother. Currently, the only way of diagnosing fetal genetic or chromosomal abnormalities is by invasive techniques, such as chorionic villous sampling (CVS) and amniocentesis performed at 10 to 13 weeks and after 15 weeks of gestation, respectively. Although small, there is a risk for fetal loss with these procedures. Transcervical cell sampling (TCS), similar to a Pap smear, is a platform that meets the requirements for prenatal genetic testing (genetic testing with fetal cells obtained before birth), as well as diagnosis of maternal pregnancy complication, at a very early stage of pregnancy (as early as 5 weeks) and carries low risk for the mother and the developing fetus.\n\nThis study will examine cervical fluid collected using various noninvasive methods for TCS in pregnant women. The number of placental cells will be assessed against similarly obtained samples from nonpregnant women of reproductive age who lack cells derived from a placenta. Participating volunteers will provide written informed consent. Only standard medical procedures and approved devices will be used for collection of cervical fluid, minimizing risk to the participants and their fetuses. No test results or other benefits will be available to the participants.",[26,111,89,87],"Inherited Genetic Conditions (Diagnosis)","2024-03-14",{"date":114,"type":36},"2024-03-21",{"date":95,"type":19},{"date":117,"type":19},"2031-02-28",{"name":119,"class":43},"Dr. Sascha Drewlo"]